Search bioRxiv⌕ Search

Biology subjects

Heemskerk, M. H.

Publications and source records attributed to Heemskerk, M. H..

3 recordsLinked to original sources

Distinct Effects of the Extracellular Matrix on Tumor Organization and Response to Cancer Virotherapy

Extracellular matrix (ECM) regulates tumor architecture and immune accessibility, but its impact on virus-based anticancer therapies is not well understood. In particular, ECM modulation leads to both enhanced and impaired therapeutic outcomes in vivo, reflecting the complexity of matrix-immune-virus interactions. Here, we combine computational modeling with empirical 3D tumor spheroid-immune in vitro co-cultures to examine how ECM composition and abundance shape an Alphavirus replicon-based therapy. We show that ECM-induced changes in tumor spheroid architecture vary by cell-adhesion phenotype but higher matrix abundance consistently reduces cellular density. Notably, increasing abundance of basement membrane extract or Collagen-I reduced tumor spheroid cell density, which generally enhanced viral infection, T cell activation, and IFN{gamma} production. However, reduced immune accessibility in collagen-rich environments suppressed immune responses despite improved infection, highlighting matrix-specific effects. Our findings provide insights into ECMs role in virus-based therapies and propose a bottom-up framework for systematically evaluating its influence on therapeutic efficacy.

cancer biology↗

Temperature-based MHC class-I multimer peptide exchange for human HLA-A, B and C

T cell recognition of specific antigens presented by major histocompatibility complexes class-I (MHC-I) can play an important role during immune responses against pathogens and cancer cells. Detection of T cell immunity is based on assessing the presence of antigen-specific cytotoxic CD8+ T cells using MHC class-I (MHC-I) multimer technology. Previously we have designed conditional peptides for HLA-A*02:01, H-2Kb and HLA-E that form stable peptide-MHC-I-complexes at low temperatures and dissociate when exposed to a defined elevated temperature. The resulting conditional MHC-I complex can easily and without additional handling be exchanged with a peptide of interest, allowing to exchange peptides in a ready-to-use multimer and a high-throughput manner. Here we present data that this peptide-exchange technology is a general applicable, ready-to-use and fast approach to load many different peptides in MHC-I multimers for alleles of the HLA-A, HLA-B and HLA-C loci. We describe the development of conditional peptides for HLA-A*03:01, HLA-A*11:01, HLA-B*07:02 and HLA-C*07:02 that only form stable peptide-MHC-I complexes at low temperatures, allowing peptide exchange at higher defined temperature. We document the ease and flexibility of this technology by monitoring CD8+ T cell responses to virus-specific peptide-MHC complexes in patients. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=77 SRC="FIGDIR/small/630039v2_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@1a48592org.highwire.dtl.DTLVardef@3d5f24org.highwire.dtl.DTLVardef@13160b7org.highwire.dtl.DTLVardef@c4bb19_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIT cell immunity relies on antigen-specific CD8+ T cells recognizing peptide MHC-I complexes. C_LIO_LIEstablishing temperature-based peptide exchange across multiple HLA alleles, resulting in a robust, easy, and fast system to generate peptide MHC-I complexes. C_LIO_LITemperature-based MHC class-I multimer demonstrate applicability across major MHC-I gene families for monitoring CD8+ T cell responses. C_LIO_LIEasy high-throughput peptide exchange potential, enhancing clinical utility of MHC multimer technology. C_LI

immunology↗

SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells

Detection of SARS-coronavirus-2 (SARS-CoV-2) specific CD4+ and CD8+ T cells in SARS-CoV-2-unexposed donors has been explained by the presence of T cells primed by other coronaviruses. However, based on the relative high frequency and prevalence of cross-reactive T cells, we hypothesized CMV may induce these cross-reactive T cells. Stimulation of pre-pandemic cryo-preserved PBMCs with SARS-CoV-2 peptides revealed that frequencies of SARS-CoV-2-specific T cells were higher in CMV-seropositive donors. Characterization of these T cells demonstrated that membrane-specific CD4+ and spike-specific CD8+ T cells originate from cross-reactive CMV-specific T cells. Spike-specific CD8+ T cells recognize SARS-CoV-2 spike peptide FVSNGTHWF (FVS) and dissimilar CMV pp65 peptide IPSINVHHY (IPS) presented by HLA-B*35:01. These dual IPS/FVS-reactive CD8+ T cells were found in multiple donors as well as severe COVID-19 patients and shared a common T cell receptor (TCR), illustrating that IPS/FVS-cross-reactivity is caused by a public TCR. In conclusion, CMV-specific T cells cross-react with SARS-CoV-2, despite low sequence homology between the two viruses, and may contribute to the pre-existing immunity against SARS-CoV-2.

immunology↗